Diabetic nephropathy
Conditions
Interventions
Finerenone treatment group:None
Sponsors
Peking University third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) patients aged 18-80 years old; (2) type 2 diabetes mellitus; (3) clinically diagnosed chronic kidney disease and meeting the following criteria: 1) eGFR >= 25ml/min/1.73m^2; 2) UACR > 30mg/g and <= 5000mg/g ; 3) Type 2 diabetes, chronic kidney disease, blood pressure and lipid lowering drugs have not been replaced within 4 weeks before obtaining informed consent; 4)HbA1c<7% ; 5) patients with hypertension have been given ACEI/ARB/ARNI, and their blood pressure is controlled at SBP < 140mm HgMagneDBP < 90mmHg; 6) sign informed consent. The above inclusion criteria need to be met.
Exclusion criteria
Exclusion criteria: (1) UACR > 5000mg/g or eGFR 4.8mmol/L ; (5) heart function II-IV (NYHA class) patients with decreased ejection fraction or left ventricular ejection fraction <= 35%; (6). One of the following occurs within 8 weeks prior to informed consent: 1) Ischemic Stroke or transient Ischemic attack; 2) Acute Coronary Syndrome ; 3) hospitalization due to heart failure or deterioration of renal function ; (7) planned coronary revascularization or other cardiovascular surgery or percutaneous interventional therapy during observation ; (8) planned kidney transplant or dialysis during observation; (9) severe liver. Dysfunctional (Child-PughC); (10) receiving itraconazole, Clarithromycin. Or patients with CYP3A4 potent inhibitors or inducers such as ritonavir, azanavir, dalunavir, fosanavir, coblistat (discontinue use at least 7 days before admission) ; (11) patients with Addison' s disease; (12) patients with active infectious diseases; (13) pregnant or possibly pregnant or lactating patients; (14) other patients in this study (including, but not limited to, renal artery stenosis, renal artery stenosis. Single kidney or active malignant tumor)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| reactive hyperemia index;Pulse wave conduction velocity;blood routine examination; | — |
Secondary
| Measure | Time frame |
|---|---|
| Non-mydriatic fundus photography;urinary protein quantification;urinary total protein;urinary creatinine;urinary total protein/creatinine;N-acetyl-ß-D glucaminoglycosidase;nitric oxide;endothelin;cystatin C;serum biochemical;endothelial selectin; | — |
Countries
China
Contacts
Public ContactZu Lingyun
Peking University third Hospital
Outcome results
None listed